Applied BioCode (6598) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · ABC-KY

Applied BioCode (6598) reported revenue of NT$35.8 million for Oct 2026, +8.7% year on year and -53.7% from the previous month. Revenue for Jan–Oct 2026 was NT$648 million (+65.5% year on year).

Year-on-year revenue growth: 12 months in a row. →

In Oct 2026, it ranked No. 112 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$43.2 million24/10Nov 2024 NT$18.4 millionDec 2024 NT$23.2 millionJan 2025 NT$42.1 millionFeb 2025 NT$39.7 million25/02Mar 2025 NT$38.3 millionApr 2025 NT$43 millionMay 2025 NT$25.7 millionJun 2025 NT$48.4 million25/06Jul 2025 NT$41.5 millionAug 2025 NT$37.2 millionSep 2025 NT$44.5 millionOct 2025 NT$32.9 million25/10Nov 2025 NT$29.2 millionDec 2025 NT$54.5 millionJan 2026 NT$79 millionFeb 2026 NT$71.9 million26/02Mar 2026 NT$66 millionApr 2026 NT$61 millionMay 2026 NT$60.3 millionJun 2026 NT$88.9 million26/06Jul 2026 NT$46 millionAug 2026 NT$60.9 millionSep 2026 NT$77.2 millionOct 2026 NT$35.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$35.8 million+8.7%-53.7%
Sep 2026NT$77.2 million+73.7%+26.7%
Aug 2026NT$60.9 million+64.0%+32.6%
Jul 2026NT$46 million+10.7%-48.3%
Jun 2026NT$88.9 million+83.5%+47.4%
May 2026NT$60.3 million+134.9%-1.1%
Apr 2026NT$61 million+41.8%-7.6%
Mar 2026NT$66 million+72.5%-8.2%
Feb 2026NT$71.9 million+81.3%-9.0%
Jan 2026NT$79 million+87.9%+44.9%
Dec 2025NT$54.5 million+134.7%+87.0%
Nov 2025NT$29.2 million+58.8%-11.4%
Oct 2025NT$32.9 million-23.7%-25.9%
Sep 2025NT$44.5 million+139.6%+19.7%
Aug 2025NT$37.2 million+125.4%-10.5%
Jul 2025NT$41.5 million+4.0%-14.3%
Jun 2025NT$48.4 million+32.2%+88.7%
May 2025NT$25.7 million-17.3%-40.3%
Apr 2025NT$43 million+25.7%+12.4%
Mar 2025NT$38.3 million+98.7%-3.5%
Feb 2025NT$39.7 million+75.3%-5.7%
Jan 2025NT$42.1 million+6.5%+80.9%
Dec 2024NT$23.2 million-36.7%+26.5%
Nov 2024NT$18.4 million-76.1%-57.4%
Oct 2024NT$43.2 million+186.8%+132.5%

Jan–Oct 2026 cumulative: NT$648 million (+65.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Applied BioCode vs PEC / Applied BioCode vs Lotus Pharm / Applied BioCode vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本年度累積營收增長,主係市場開發成果與客戶需求提升,致使出貨增加。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16